Fluorouracil, Oxaliplatin, and Zolbetuximab
About
Membership operator: AND
Therapies: 3
Therapies
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) FDA (2) | CLDN18.2 >= 75%, HER2-negative | Adenocarcinoma of the Gastroesophageal Junction | Fluorouracil, Oxaliplatin, Zolbetuximab |